Recent developments for Masimo include the board's backing of Danaher's $9.9 billion acquisition proposal, completion of the sale of its non-healthcare consumer business, and notable stock price movements following acquisition news.

• Masimo's board backed Danaher's $9.9 billion cash acquisition proposal in February 2026, signaling support for the transaction [N4].
• Following the acquisition announcement, Masimo's stock experienced a 34% surge, reflecting market reaction to the deal [N1].
• The company completed the sale of its non-healthcare consumer business, Sound United, in September 2025, focusing on its core healthcare segment [N1].
• Danaher strengthened its diagnostics capabilities through the $9.9 billion Masimo acquisition, highlighting strategic value in the deal [N8].

Masimo's advanced monitoring technologies and integrated platforms position it well within the growing healthcare technology sector. The company's recurring revenue model through sensor purchase commitments provides a stable revenue base. The strategic divestiture of non-core consumer businesses allows focus on healthcare. The board's support of Danaher's $9.9 billion acquisition proposal reflects confidence in the company's value and potential synergies. Experienced leadership and a strong product portfolio support continued operational execution.

Masimo reported a net loss for the fiscal year ended January 3, 2026, indicating challenges in profitability. The healthcare sector is competitive, with rapid technological changes and regulatory risks. The company's reliance on deferred equipment agreements requires sustained sensor sales to maintain revenue. Integration risks exist related to the proposed acquisition by Danaher. Market and operational risks include customer concentration, reimbursement changes, and potential litigation. The divestiture of non-healthcare businesses may reduce diversification.

Masimo's moat is built on proprietary technology in noninvasive monitoring, including patented sensors and integrated software platforms that enable hospital automation and telehealth. The company's deferred equipment agreements create recurring revenue streams through sensor purchase commitments, fostering customer lock-in. Its broad direct sales network, OEM partnerships, and established relationships with healthcare providers support market penetration and competitive positioning. The company's operational expertise and innovation in patient monitoring contribute to barriers to entry for competitors.

• Profitability Risk: Masimo reported a net loss of $151.5 million for fiscal year 2025, reflecting challenges in achieving consistent profitability.
• Acquisition and Integration Risk: The $9.9 billion acquisition proposal by Danaher introduces risks related to deal completion, integration, and potential changes in strategic direction.
• Market and Competitive Risk: The medical technology sector is highly competitive with rapid innovation cycles, requiring continuous investment in R&D and market adaptation.
• Revenue Concentration Risk: Revenue depends significantly on deferred equipment agreements with multi-year sensor purchase commitments, requiring sustained customer demand.
• Regulatory and Legal Risk: Healthcare products are subject to regulatory approvals and potential litigation, which could impact operations and financial results.

• Masimo Corporation is a global medical technology company developing and producing monitoring technologies including measurements, sensors, and patient monitors.
• Masimo's products are powered by the Masimo Hospital Automation™ and Masimo SafetyNet® platforms, offering connectivity, automation, telehealth, and telemonitoring solutions for hospital and out-of-hospital care.
• The company operates one reportable segment: healthcare, as of September 27, 2025.
• Healthcare products include monitors or circuit boards, proprietary single-patient use or reusable sensors, software, and cables.
• Masimo sells primarily to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and long-term care facilities via direct sales, distributors, and OEM partners.
• The former non-healthcare consumer business, including audio and home integration technologies, was classified as held-for-sale and sold in 2025.
• Revenue is derived mainly from four sources: deferred equipment agreements with sensor purchase commitments, direct sales of monitoring solutions, sales to distributors, and sales of integrated circuit boards to OEM customers.
• Deferred equipment agreements involve providing equipment at no upfront charge in exchange for multi-year sensor purchase commitments, typically 3-6 years.
• Revenue recognition involves allocation of contract consideration to lease and non-lease components, with sales-type and operating lease distinctions.
• As of January 3, 2026, Masimo had cash and cash equivalents of $152.3 million, current assets of $926 million, and current liabilities of $371.6 million, resulting in a current ratio of 2.49 and a cash ratio of 0.41.
• For fiscal year ended January 3, 2026, Masimo reported a net loss of $151.5 million and diluted EPS of -2.8 USD per share.
• The company is a large accelerated filer and files reports with the SEC regularly, including 10-K/A and 10-Q filings.
• Masimo's board includes experienced directors with deep medical device and operational expertise, including CEO Catherine Szyman appointed in February 2025.
• In early 2026, Masimo's board backed Danaher's $9.9 billion cash acquisition proposal.
• Masimo completed the sale of its non-healthcare consumer business, Sound United, in September 2025.
• The company had 53.7 million shares outstanding as of September 27, 2025.
• Masimo's recent news highlights include the acquisition proposal by Danaher, a 34% stock price surge following the acquisition announcement, and ongoing business divestitures and strategic moves.